Fingerprint
Dive into the research topics where Patrick Smith is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants & Projects
- 4 Finished
-
A Multi-Center, Open Label, Multi-Dose, Three Period, Single-Sequence Crossover Study
Bednarczyk, E. (PI) & Smith, P. (PI)
10/18/06 → 10/18/07
Project: Research
-
In Vitro Pharmacokinetic/Pharmacodynamics of LBH589 in Chronic Myelogenous Leukemia
Smith, P. (PI)
Novartis Pharmaceuticals Corporation
08/7/06 → 09/30/07
Project: Research
-
Effects of Quinidine or Rifampin Co-administration on the Single-Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants
Rask-Madsen, C., Katragadda, S., Li, M., Ucpinar, S., Chinn, L., Arora, P. & Smith, P., Jun 2024, In: Clinical Pharmacology in Drug Development. 13, 6, p. 590-600 11 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
Kamal, M. A., Ganguly, S., Kadambi, A. & Smith, P. F., Sep 2024, In: Clinical Pharmacology and Therapeutics. 116, 3, p. 518-521 4 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Asia-Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo
Venkatakrishnan, K., Gupta, N., Smith, P. F., Lin, T., Lineberry, N., Ishida, T., Wang, L. & Rogge, M., Feb 2023, In: Clinical Pharmacology and Therapeutics. 113, 2, p. 298-309 12 p.Research output: Contribution to journal › Article › peer-review
Open Access15 Scopus citations -
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results
on behalf of the 503 and RSV2004 Study Groups, Jul 2023, In: PLOS ONE. 18, 7 July, e0288271.Research output: Contribution to journal › Article › peer-review
Open Access25 Scopus citations -
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants
Ucpinar, S., Smith, P. F., Long, L., Li, F., Yan, H., Wadhwa, J., Chu, K. A., Shu, J., Nunn, P. & Li, M., Jul 2023, In: Clinical and Translational Science. 16, 7, p. 1210-1219 10 p.Research output: Contribution to journal › Article › peer-review
Open Access15 Scopus citations